Le Chevalier T, Arriagada R, Pico J L, Rouësse J, Hayat M, Duroux P, Baldeyrou P, Homasson J P
Bull Cancer. 1982;69(1):98-101.
Two non randomized therapeutic trials have been conducted in oat cell carcinoma of the lung with limited disease. The first protocol combined chemotherapy (adriamycin, cyclophosphamide, VM 26, procarbazine) with mediastinal and supra-clavicular radiotherapy in classical fractionation (40 grays in 4 weeks). The second combined a more intensive chemotherapy (adriamycin, VP 16, methotrexate, cyclophosphamide) with an alternating radiotherapy (3 series of 15 grays). All patients received prophylactic brain irradiation. Preliminary results show a 9 month survival rate of 34 per cent and 62.5 per cent respectively. In addition, all patients in the second protocol presented a complete response at the end of the induction treatment. These preliminary data encourage proceeding with this kind of combined treatment.
针对局限性疾病的肺燕麦细胞癌，已开展了两项非随机治疗试验。第一个方案将化疗（阿霉素、环磷酰胺、VM 26、丙卡巴肼）与纵隔和锁骨上区常规分割放疗（4周内40格雷）相结合。第二个方案将强度更大的化疗（阿霉素、VP 16、甲氨蝶呤、环磷酰胺）与交替放疗（3个疗程，每个疗程15格雷）相结合。所有患者均接受了预防性脑照射。初步结果显示，9个月生存率分别为34%和62.5%。此外，第二个方案中的所有患者在诱导治疗结束时均出现完全缓解。这些初步数据鼓励继续开展此类联合治疗。
